Grace: seeking cures in pathological roots

Grace Science hopes to parlay discovery of rare disease target into therapies for orphan, non-orphan diseases

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer.

Grace Science LLC’s origins stem from the diagnosis of co-founder and CEO Matt Wilsey’s daughter Grace with NGLY1 deficiency in 2013.

The disease results from mutations reducing the activity of NGLY1, a deglycosylation enzyme that promotes proteasomal degradation. First proposed as a disorder in 2012, Wilsey said less than 60

Read the full 738 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE